Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05538754 · ClinicalTrials.gov registry record · NA

Post-Market Evaluation of the EVO ICL

A NA study of Myopia and Myopic Astigmatism, sponsored by Staar Surgical Company.

Completed
Registry status
NA
Development phase
205
Enrollment target
8
Study locations

NCT05538754: Completed NA study of Myopia and Myopic Astigmatism, sponsored by Staar Surgical Company.

NCT05538754 is a NA study of Myopia and Myopic Astigmatism that has completed, run by Staar Surgical Company. The registered enrollment target is 205 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (23% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05538754, a NA study of Myopia and Myopic Astigmatism, has completed, sponsored by Staar Surgical Company.

COMPLETED
Registry status
NA
Development phase
205 participants
Enrollment target
8
Study locations

Study Summary

The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).

Interventions

  • DEVICE EVO ICL

Study Locations (8)

Texas

  • Key-Whitman Eye Center - Dallas
  • Parkhurst NuVision - San Antonio

Hawaii

  • Aloha Laser Vision, LLC - Honolulu

Kansas

  • Durrie Vision - Overland Park

Nebraska

  • Kugler Vision, PC - Omaha

Ohio

  • Cleveland Eye Clinic - Brecksville

South Dakota

  • Vance Thompson Vision - Sioux Falls

Utah

  • The Eye Institute of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 205 participants
Start Date 2022-09-23
Est. Completion 2023-10-04
Phase NA

Sponsor

Staar Surgical Company

3 total trials

What the Registry Record Tells You About NCT05538754

The ClinicalTrials.gov registry entry for NCT05538754 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (23% lower). The listed sponsor is Staar Surgical Company, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which EVO ICL is the first listed.

NCT05538754 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, Hawaii, Kansas.

Frequently Asked Questions

What is clinical trial NCT05538754 about?

NCT05538754 is a clinical study titled "Post-Market Evaluation of the EVO ICL". The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).

What is the current status of trial NCT05538754?

This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2022-09-23. Estimated completion is 2023-10-04.

What conditions does trial NCT05538754 study?

This clinical trial studies the following conditions: Myopia, Myopic Astigmatism.

What interventions are being tested in trial NCT05538754?

The interventions under investigation include: EVO ICL (DEVICE).

Who is sponsoring clinical trial NCT05538754?

This trial is sponsored by Staar Surgical Company, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05538754 being conducted?

This trial has 8 study locations across Hawaii, Kansas, Nebraska, Ohio, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.